3933 On Other Exchanges
Symbol
Exchange
3933 is not on other exchanges.

the united laboratories inte (3933) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THE UNITED LABORATORIES INTE (3933)

Related News

No related news articles were found.

the united laboratories inte (3933) Related Businessweek News

No Related Businessweek News Found

the united laboratories inte (3933) Details

The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products. It operates in three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers antibiotic and non-antibiotic finished products, insulin products, and soft capsules casings, as well as produces and sells bulk medicines, pharmaceutical intermediate products, and organic fertilizers. It is also developing biological preparations, including insulin degludec and liraglutide; and chemical pharmaceuticals comprising antidiabetic drugs, anti-cancer drugs, anti-HBV drugs, and high-end antibiotics. In addition, the company trades in pharmaceutical products. It operates primarily in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and other regions. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited operates as a subsidiary of Heren Far East Limited.

11,700 Employees
Last Reported Date: 04/27/17
Founded in 1990

the united laboratories inte (3933) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $3.8M
Vice Chairman, Chief Financial Officer and Co...
Total Annual Compensation: $3.7M
Vice President, General Manager of China Sale...
Total Annual Compensation: $2.6M
Vice President and Executive Director
Total Annual Compensation: $2.6M
Vice President and Executive Director
Total Annual Compensation: $2.6M
Compensation as of Fiscal Year 2016.
the united laboratories inte
The United Laboratories International Holdings Limited, Annual General Meeting, Jun 08, 2017

The United Laboratories International Holdings Limited, Annual General Meeting, Jun 08, 2017, at 11:00 China Standard Time. Location: Conference Room (A3), 1804, 18th Floor, Tower 1 Admiralty Centre, 18 Harcourt Road Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements and the reports of the directors and auditor for the year ended 31 December 2016; to consider board changes; to authorise the board of directors to fix the directors' remuneration; to re-appoint Deloitte Touche Tohmatsu as the Company's auditor and authorise the board of directors to fix their remuneration; to grant a general mandate to the directors to issue, allot and otherwise deal with the Company's securities; to grant a general mandate to the directors to repurchase the Company's shares; and to extend the general mandate to the directors to issue the securities of the Company.

The United Laboratories International Holdings Limited Reports Audited Consolidated Cash Flows for the Year Ended December 31, 2016

The United Laboratories International Holdings Limited reported audited consolidated cash flows for the year ended December 31, 2016. For the period, the company’s net cash from operating activities was HKD 1,375,525,000 against HKD 1,809,551,000 a year ago. Payments for purchase of property, plant and equipment was HKD 463,547,000 against HKD 722,890,000 a year ago. Addition to intangible assets was HKD 77,296,000 against HKD 49,017,000 a year ago.

The United Laboratories International Holdings Limited Reports Audited Consolidated Earnings Results for the Year Ended 31 December 2016

The United Laboratories International Holdings Limited reported audited consolidated earnings results for the year ended 31 December 2016. For the year, turnover was HKD 7,062,571,000 against HKD 7,694,563,000 a year ago. Loss before taxation was HKD 154,551,000 against profit of HKD 235,422,000 a year ago. Loss for the year attributable to owners of the Company was HKD 311,294,000 or 19.13 cents per basic and diluted share against profit of HKD 110,358,000 or 6.78 cents per basic and diluted share a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

3933 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3933.
View Industry Companies
 

Industry Analysis

3933

Industry Average

Valuation 3933 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact THE UNITED LABORATORIES INTE, please visit www.tul.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.